Sign in with Google
bullish
Samsung Biologics (207940 KS): Gaining Momentum on New Approval and Contract Wins; Hold Shares
426 Views02 Jul 2024 12:12
SUMMARY
- Samsung Biologics (207940 KS) has signed the largest ever single CMO contract worth KRW1.46T ($1.1B) with an undisclosed U.S.-based pharmaceutical company. The contract value represents ~40% of 2023 standalone revenue.
- Within the first half of the year, Samsung Biologics has secured order worth of KRW2.6T, compared with order win of KRW3.5T in full-year 2023.
- Samsung Bioepis has received FDA approval for Stelara biosimilar Pyzchiva, which is expected to marketed in early 2025. So far, the FDA has approved two other biosimilars of Stelara.
Related Insights
More »Loading
Trending Collections
More »Trending Insights
More »- Goldlion Holdings (533 HK): An Unexpected HK Arbageddon
- [Japan M&A] Bloomberg Reports Bain MBO on Nissin (9066) May Come Monday - The Implied Price Is Light
- Nissin Corp (9066 JP): A Rumoured Bain-Sponsored MBO?
- Zijin Mining Group: Undervalued, Diversified, and Scaling Fast
- The Coming Global Trade Re-Ordering
Top Unpaywalled Insights
More »- The Coming Global Trade Re-Ordering
- The Polycrisis Era (2025–2028): Navigating a World of Overlapping Disruptions
- Our AI-Powered Accounting Risk Trading Strategy Beat the S&P 500 by 2.5x
- India-UK Free Trade Agreement: A New Era for India's Textile Industry
- The Rise of Quant Investing in Crypto w/ Truvius CEO Connor Farley | The New Barbarians #007
Discussions
(Paid Plans Only)
Price Chart(Sign Up to Access)
- Samsung Biologics (207940 KS): Record High Revenue in 2024; Accelerated Growth Expected in 202522 Jan 2025
- Samsung Biologics (207940 KS): 3Q Result Beat Expectation; Guidance Raise Amid Increasing Order Book23 Oct 2024
- Samsung Biologics (207940 KS): Strong 2Q24 Result; Annual Revenue to Surpass KRW4 Trillion25 Jul 2024
- Samsung Biologics (207940 KS): Mixed 1Q24 Result; Order Book Swells; New Drug Approval in Europe24 Apr 2024
- Samsung Biologics (207940 KS): Stellar Performance in 4Q23; Outlook Remains Strong27 Jan 2024
- Samsung Biologics (207940 KS): Better-Than-Expected 3Q23 Result; Sees 20%+ Annual Revenue Growth26 Oct 2023
x